Bharti Airtel hits new high, up 40% in 1 year; brokerages see more upside

Bharti Airtel share price today: Shares of Bharti Airtel hit a record high of ₹1,924, as they rallied 3 per cent on the BSE in Friday's intra-day trade on the back of heavy volumes amid a healthy outlook.
The stock price of the telecom services provider has surpassed its previous high of ₹1,916.90, which it touched on May 7, 2025.
Thus far in the calendar year 2025, Bharti Airtel has outperformed the market by surging 20 per cent, as compared to a 4.5 per cent rise in the BSE Sensex. In the past year, the stock zoomed 40 per cent, as against a 6 per cent gain in the benchmark index.
Reliance Jio initial public offering
Mukesh Ambani's telecom giant, Reliance Jio, is reportedly planning an initial public offering (IPO) in the second half of 2025, aiming to be the largest IPO in India. According to media reports, Jio Platforms is estimated to have an enterprise value (EV) in the range of $136 billion-$154 billion at its peak.
JM Financial, Mirae Asset Sharekhan see more upside
Analysts at JM Financial Institutional Securities have raised Bharti's FY26-27 consolidated Ebitda estimate by 10 per cent, accounting for Indus consolidation. Hence, there is a marginal 0-1 per cent increase in profit after tax (PAT) estimate and a slight increase in target price (TP) to ₹2,050 apiece, from ₹2,035 per share earlier.
The brokerage firm in its June 9, 2025, telecom report said that it reiterates a 'Buy' rating on Bharti Airtel as analysts believe India's wireless business tariff hikes are likely to be more frequent given the consolidated industry structure. Higher average revenue per user or ARPU requirement for Jio is not only to justify its significant 5G capex, but also given its potential listing plans. Bharti is the biggest beneficiary of higher tariffs, given the sticky and premium quality of its subs.
ARPU growth aided by likely moderation in capex will continue to drive Bharti's free cash flow (FCF), enabling it to get to net cash by FY30; this will also aid in accretion in equity value. However, there is a possibility of continued stake sale by promoters to outside investors, which could be a near-to-medium term overhang as Singtel (effective stake at ~28.3 per cent) and the Mittal family (effective stake at ~22.9 per cent) plan to equalise their stake over a period of time.
According to Mirae Asset Sharekhan, Bharti Airtel has delivered a robust performance in FY25, achieving strong revenue and Ebitda growth despite challenges such as African currency devaluation, with a focus on operational excellence and deleveraging, strengthening its balance sheet.
The company is making significant strides in mobile, broadband, and digital TV segments, which are expected to be bolstered further by strategic partnerships like Apple TV and Starlink, while continuing to invest in 5G and fibre expansion.
The company continues to achieve industry-leading ARPU for India mobile services, while traction from adjacent businesses and moderation of capex intensity is likely to further deleverage the balance sheet, the brokerage firm said; maintain 'buy' rating on stock with a target price of ₹2,170 per share.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

23 minutes ago

• Business Standard

Nippon India MF, BlackRock, others buy 10% stake in Sai Life for ₹1,505 cr

Nippon India Mutual Fund, BlackRock, Societe Generale, Morgan Stanley and others on Friday collectively bought a 10 per cent stake in Sai Life Sciences from US-based asset manager TPG for Rs 1,505 crore through open market transactions. Besides, Axis Mutual Fund (MF), Aditya Birla Sun Life MF, Invesco MF, Norway's Government Pension Fund Global, German multinational Allianz's arm Pimco, Axis Max Life Insurance, HDFC MF, Ghisallo Master Fund LP, UTI MF, DSP MF were among the buyers of Sai Life Sciences shares. These entities picked up more than 2.08 crore equity shares or 10 per cent stake in Hyderabad-based Sai Life Sciences, as per the block deal data on the BSE. The transaction, valued at around Rs 1,504.75 crore, was executed at an average price of Rs 722 apiece. Meanwhile, Nippon India MF picked up 49.86 lakh shares or 2.39 per cent holding in Sai Life Sciences. After the stake buy, Nippon India MF's stake in the company rose to 4.88 per cent from 2.48 per cent. Meanwhile, global asset manager TPG through its affiliate TPG Asia VII SF offloaded the equal number of shares in 25 tranches at the same price. Following the stake sale, TPG's holding in Sai Life Sciences declined to 14.73 per cent from 24.73 per cent. Shares of Sai Life Sciences rose 5.03 per cent to close at Rs 765.85 apiece on the BSE. In December last year, Sai Life Sciences raised Rs 3,043 crore through its initial public offering and the shares of the company made a stellar debut on the bourses. Sai Life Sciences provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms.

Business Standard

23 minutes ago

• Business Standard

BSNL launches country's first indigenous 5g fixed wireless service

State-owned telecom firm BSNL has forayed into 5G fixed wireless service to provide home broadband service with its launch in Hyderabad, the company said on Friday. At present, Reliance Jio and Bharti Airtel have been providing 5G Fixed Wireless Service (FWA) by using their 5G spectrum. "Quantum 5G FWA demonstrates how Indian engineers can create world-class connectivity. It is the first SIM-less, 100 per cent home grown customised 5G FWA for BSNL. Today is only a soft launch - many more cities and feature upgrades will follow," BSNL Chairman and Managing Director A Robert J Ravi said. The service was launched on June 18. According to the details shared by BSNL, the company will expand the pilot project in Bengaluru, Pondicherry, Vishakhapatnam, Pune, Gwalior and Chandigarh by September 2025. The company is initially charging Rs 999 for a 100 megabit per second (mbps) plan and Rs 1,499 for a 300 mbps plan. Through 5G FWA, telecom operators install a modem outside the subscriber's premise and transmit signals from their nearest base station for wireless broadband service. The technology does not require optical fibre for connection. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Economic Times

an hour ago

• Economic Times

TPG offloads Rs 1,505 cr stake in Sai Life via block deals; Norges Bank, MFs step in

Global investor TPG sold its ₹1,505 crore stake in Sai Life Sciences via block deals at ₹722 per share. Key buyers included Norges Bank and top Indian mutual funds. The stock rallied 5% post-deal, reflecting robust investor appetite. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Global investment firm TPG offloaded stake worth Rs 1,505 crore in Sai Life Sciences through block deals on Friday, paving the way for a host of marquee investors to step in, including Norges Bank and leading Indian mutual sold over 2 crore shares in two tranches at Rs 722 per share, a price that reflected a 1% discount to Thursday's closing the key buyers, Norway's central bank, Norges Bank, acquired 11.5 lakh shares worth Rs 83 crore, signaling strong foreign institutional interest in the Indian pharmaceutical the domestic front, several top mutual funds participated in the transaction:-- Nippon India Mutual Fund bought over 40 lakh shares for Rs 290 crore,-- Invesco Mutual Fund acquired 13.5 lakh shares worth Rs 97.5 crore, and-- Aditya Birla Sun Life Mutual Fund picked up 13.85 lakh shares for Rs 100 appetite appeared strong, as shares of Sai Life Sciences rallied 5% to close at Rs 765.85 on the BSE following the block stake reshuffle highlights the growing confidence of both global and domestic institutional investors in Sai Life's long-term growth prospects amid the increasing relevance of India in the global pharma outsourcing held over 5.15 crore equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at Rs 15,230 crore. The stock of Sai Life Sciences was listed on the exchanges on December 18, stock has gained nearly 2% since its listing on December 18, 2024 and its returns on the year-to-date basis remain at 3%. This is an underperformance versus Nifty which has given returns of 6.6% and 5.7%, Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers. The company has operations in the UK, the USA and company reported a 57% year-on-year profit in its Q4FY25 net profit at Rs 88 crore versus Rs 56 crore reported in the year ago period. The total revenue from operations in the January-March quarter of FY25 stood at Rs 589 crore, which was growth of 33% versus Rs 443 crore posted by the company in the corresponding quarter of the previous financial to Trendlyne data, shares of Sai Life Sciences are trading above its 50-day and 100-day simple moving averages (SMAs) of Rs 727 and Rs 715, stock has been quite volatile since the last 3 months. Its 1-year beta is at 1.4.